Cancer-associated retinopathy is an autoimmune disease in which autoantibodies trigger retinal tissue destruction.1 Patients with cancer-associated retinopathy may develop visual acuity or visual field loss, photopsias, photophobia, and/or nyctalopia.1 Drug-induced toxic effects can also cause photoreceptor damage and corresponding visual symptoms.2 We describe a patient with nyctalopia during treatment of non–small cell lung cancer with AUY922, a heat shock protein 90 (HSP90) inhibitor.3
Munk MR, Fernandes J, Mets M, Patel JD, Johnson ML, Jampol LM. Reversible Nyctalopia and Retinopathy in a Patient With Metastatic Cancer Treated With Anti–Heat Shock Protein 90 Therapy. JAMA Ophthalmol. 2014;132(7):899–901. doi:10.1001/jamaophthalmol.2014.409
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.